Abstract
Background Few studies have reported on the diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) LR-5 or LR-5 V in the diagnosis of hepatocellular carcinoma (HCC) using MRI with gadoxetate disodium. Purpose To determine the diagnostic performance of LI-RADS version 2018 (hereafter, v2018) on gadoxetate disodium-enhanced MRI in comparison with LI-RADS version 2017 (hereafter, v2017) for the diagnosis of HCC in patients with cirrhosis or chronic hepatitis B viral infection or at high risk for HCC. Materials and Methods This retrospective study between January 2013 and October 2015 evaluated consecutive patients at high risk for HCC who had at least one observation of 10 mm or greater on gadoxetate disodium-enhanced MRI and no history of previous treatment for hepatic lesions. MRI features were reviewed by three radiologists. Observations were categorized according to LI-RADS v2018 and LI-RADS v2017. Per-observation sensitivity and specificity of LR-5 using LI-RADS v2017 and v2018 were compared using generalized estimating equation models. Results A total of 422 observations, including 234 HCCs confirmed by results of pathologic examination in 387 patients (305 men and 82 women; mean age ± standard deviation, 59 years ± 10), were included. In all observations, LI-RADS v2018 provided higher sensitivity than LI-RADS v2017 (81% [189 of 234] vs 68% [160 of 234], respectively; P < .001). In small observations (10-19 mm), LI-RADS v2018 yielded much higher sensitivity than LI-RADS v2017 (76% [34 of 45] vs 11% [five of 45], respectively; P < .001) with relatively little impairment of specificity (94% [121 of 128] vs 99% [127 of 128], respectively; P = .013). Conclusion Updated LR-5 criteria of Liver Imaging Reporting and Data System (LI-RADS) version 2018 on gadoxetate disodium-enhanced MRI can improve sensitivity in the diagnosis of small hepatocellular carcinomas (10-19 mm) with only slight impairment in specificity compared with the criteria of LI-RADS version 2017. © RSNA, 2019 Online supplemental material is available for this article.
Highlights
E aim of our study, was to determine the diagnostic performance of the updated LR-5 criteria of Liver Imaging Reporting and Data System (LI-RADS) v2018, in comparison with LI-RADS v2017, for the diagnosis of hepatocellular carcinomas (HCCs) in high-risk patients using MRI with gadoxetate disodium
Liver Imaging Reporting and Data System (LI-RADS) version 2018 with updated LR-5 criteria improves sensitivity for the diagnosis of small (10–19 mm) hepatocellular carcinomas on gadoxetate disodium–enhanced MRI compared with LI-RADS version 2017
Key Points nn Liver Imaging Reporting and Data System version 2018 had higher sensitivity for categorization of hepatocellular carcinomas (HCCs) as LR-5 on gadoxetate disodium–enhanced MRI compared with LI-RADS version 2017 (81% [189 of 234] vs 68% [160 of 234], respectively; P, .001)
Summary
This retrospective study between January 2013 and October 2015 evaluated consecutive patients at high risk for HCC who had at least one observation of 10 mm or greater on gadoxetate disodium–enhanced MRI and no history of previous treatment for hepatic lesions. Per-observation sensitivity and specificity of LR-5 using LI-RADS v2017 and v2018 were compared using generalized estimating equation models This retrospective cohort study was approved by the Institutional Review Board of Seoul National University Hospital and the requirement of written informed consent was waived. The inclusion criteria were as follows: (a) age of 18 years or older; (b) high risk for HCC according to LI-RADS v2017 (cirrhosis or chronic hepatitis B viral infection [Appendix E1 {online}]); (c) at least one hepatic observation 10 mm or larger, except hepatic cysts, on MRI with gadoxetate disodium; and (d) no previous treatment for hepatic lesions. 29 patients had been included in a previous study [23]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
